TRINITY BIOTECH PLC
TRIB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TRIB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TRIB
Trinity Biotech plc is a commercial-stage biotechnology company focused on diabetes management and human diagnostics, including wearable biosensors, with a strategic repositioning toward next-generation continuous glucose monitoring (CGM) and preeclampsia risk assessment.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2024.
Trinity Biotech plc is a commercial-stage biotechnology company focused on diabetes management and human diagnostics, including wearable biosensors, with a strategic repositioning toward next-generation continuous glucose monitoring (CGM) and preeclampsia risk assessment.
- Cash & equivalents of $5.2M as of 2024-12-31 [sec].
- Total revenue of $61.6M and net loss of -$31.2M for the year ended 2024-12-31 [sec].
- Shareholders' equity of -$23.9M and total debt of $106.4M as of 2024-12-31 [sec].
- CGM+ programme advancing through final design stages with pivotal clinical trials planned for 2026 [sec · filed 2026-04-30].
- Acquired Metabolomics Diagnostics Ltd. in September 2024, including its PrePsia™ preeclampsia-risk assessment technology [sec · filed 2026-04-30].
What works
- The company has an established track record of raising equity funding to support ongoing operations and CGM development [sec · filed 2026-04-30].
- CGM+ programme is advancing through final design stages with pivotal clinical trials planned for 2026, indicating progress in a high-growth biosensor area [sec · filed 2026-04-30].
- Acquisition of Metabolomics Diagnostics Ltd. adds a proprietary preeclampsia-risk assessment technology (PrePsia™) to the diagnostics portfolio [sec · filed 2026-04-30].
- Management expects capital expenditure on development projects of US$15M to US$25M in 2026, primarily for CGM and biosensor technologies and preeclampsia screening [sec · filed 2026-04-30].
What to weigh
- The company has a going concern qualification, with ability to continue dependent on generating cash flows and conducting adequate financing activities [sec · filed 2026-04-30].
- Shareholders' equity is negative (-$23.9M as of 2024-12-31) and total debt is high ($106.4M) [sec].
- Contraction and reprioritization of international funding for global health programs, including HIV-focused initiatives, materially impacted demand for legacy product lines during 2025 [sec · filed 2026-04-30].
- Clinical trials for new products are expensive, time-consuming, and uncertain; results of early trials may not be predictive of future results [sec · filed 2026-04-30].
From the filings
Quoted directly from source documents.
CGM+ programme pivotal trials planned for 2026
“The CGM+ programme is advancing through its final design stages, with pivotal clinical trials planned for 2026 as the next major development milestone.”
SEC filings · April 30, 2026
Going concern uncertainty
“Our ability to continue as a going concern depends on our ability to generate cash flows from operations and to conduct adequate financing activities.”
SEC filings · April 30, 2026
Acquisition of Metabolomics Diagnostics Ltd.
“In September 2024, we completed the acquisition of Metabolomics Diagnostics Ltd., an Irish biomarker‑development company focused on early‑pregnancy risk stratification, including its proprietary PrePsia™ preeclampsia‑risk assessment technology.”
SEC filings · April 30, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Company may not continue as a going concern without additional financing or cash from operations [sec · filed 2026-04-30].
- Clinical trial uncertainty
- High debt and negative equity — Total debt of $106.4M and negative shareholders' equity of -$23.9M as of 2024-12-31 [sec].
- Funding disruption for legacy products — Contraction of international funding for global health programs materially impacted demand for legacy product lines in 2025 [sec · filed 2026-04-30].
What to watch
- Initiation and results of pivotal clinical trials for the CGM+ programme, planned for 2026 [sec · filed 2026-04-30].
- Ability to raise additional equity or debt financing to support operations and development [sec · filed 2026-04-30].
- Progress of the PrePsia™ preeclampsia-risk assessment technology toward commercialization [sec · filed 2026-04-30].
- Stabilization of demand for legacy product lines following disruption in global health funding [sec · filed 2026-04-30].
Sources: SEC filings · Generated August 20, 2026 · How we verify sources →
Run TRINITY BIOTECH PLC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TRINITY BIOTECH PLC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
11.4 months
OCF -$4M · Net income -$31M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
21
Total value held
$86K
| Holder | Shares | Value |
|---|---|---|
| inspirion wealth advisors, llc | 25,000 | $14K |
| raymond james financial inc | 20,319 | $11K |
| becker capital management inc | 18,000 | $10K |
| renaissance technologies llc | 17,762 | $10K |
| geode capital management, llc | 16,642 | $9K |
| lpl financial llc | 15,036 | $8K |
| susquehanna international group, llp | 14,300 | $8K |
| citadel advisors llc | 14,200 | $8K |
| rhumbline advisers | 5,547 | $3K |
| jones financial companies lllp | 3,804 | $2K |
Showing top 10 of 21 institutional holders of TRINITY BIOTECH PLC. Open the full 13F history after sign-in.
Short Interest
as of Apr 24, 2026- % of float
- 2.8%
- Days to cover
- 1.2
- Shares short
- 291,283
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TRIB short interestFrequently asked questions
What is the AI investment thesis for TRINITY BIOTECH PLC?
Trinity Biotech plc is a commercial-stage biotechnology company focused on diabetes management and human diagnostics, including wearable biosensors, with a strategic repositioning toward next-generation continuous glucose monitoring (CGM) and preeclampsia risk assessment.
Who is the CEO of TRINITY BIOTECH PLC?
Mr. John Gillard is the chief executive officer of TRINITY BIOTECH PLC (TRIB).
Where is TRINITY BIOTECH PLC headquartered?
TRINITY BIOTECH PLC (TRIB) is headquartered in Bray, Ireland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.